Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association

References

• Cancer Fact Sheets. International Agency for Research on Cancer, World Health Organization; 2018 [cited 2018 Mar 3]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers?cancer=29&type=0&sex=0
   Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337.
   PubMed Web of Science ®Google Scholar
• Wang M, Yin B, Wang HY, et al. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014;6(12):1265–1278.
   PubMed Web of Science ®Google Scholar
• Goldberg JL, Sondel PM. Enhancing cancer immunotherapy via activation of innate immunity. Semin Oncol. 2015;42(4):562–572.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
   PubMed Web of Science ®Google Scholar
• Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–273.
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164):819–826.
   PubMed Web of Science ®Google Scholar
• Razin A, Friedman J. DNA methylation and its possible biological roles. Prog Nucleic Acid Res Mol Biol. 1981;25:33–52.
   PubMedGoogle Scholar
• Cardon LR, Burge C, Clayton DA, et al. Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci U S A. 1994;91(9):3799–3803.
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Miethke T, Lipford G, et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol. 1997;27(7):1671–1679.
   PubMed Web of Science ®Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329–368.
   PubMed Web of Science ®Google Scholar
• Krieg AM, YI AK, MATSON S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546–549.
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Ishii K, Gursel M, et al. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001;166(4):2372–2377.
   PubMed Web of Science ®Google Scholar
• Samulowitz U, Weber M, Weeratna R, et al. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides. 2010;20(2):93–101.
   PubMedGoogle Scholar
• Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31(7):2154–2163.
   PubMed Web of Science ®Google Scholar
• Gungor B, Yagci FC, Gursel I, et al. Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings. Oncoimmunology. 2014;3(7):e950166 eCollection.
   Web of Science ®Google Scholar
• Gungor B, Yagci FC, Tincer G, et al. CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity. Sci Transl Med. 2014;6(235):235ra61.
   PubMed Web of Science ®Google Scholar
• Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–6389.
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511.
   PubMed Web of Science ®Google Scholar
• Linch SN, Mcnamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: putting the Pedal to the Metal. Front Oncol. 2015;5:34. eCollection.
   PubMed Web of Science ®Google Scholar
• Croft M. Review Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57–78.
   PubMed Web of Science ®Google Scholar
• Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol. 2009;39(8):2184–2194.
   PubMed Web of Science ®Google Scholar
• Redmond WL, Ruby CE, Weinberg AD. Review The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol. 2009;29(3):187–201.
   PubMed Web of Science ®Google Scholar
• Lane P. Review Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med. 2000;191(2):201–206.
   PubMed Web of Science ®Google Scholar
• Bansal-Pakala P, Halteman B, Cheng M, et al. Costimulation of CD8 T cell responses by OX40. J Immunol. 2004;172(8):4821–4825.
   PubMed Web of Science ®Google Scholar
• Ladányi A, Somlai B, Gilde K, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10(2):521–530.
   PubMed Web of Science ®Google Scholar
• Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 2002;183(5):512–518.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167(3):1313–1324.
   PubMed Web of Science ®Google Scholar
• Redmond WL, Gough MJ, Charbonneau B, et al. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol. 2007;179(11):7244–7253.
   PubMed Web of Science ®Google Scholar
• Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15(3):445–455.
   PubMed Web of Science ®Google Scholar
• Gough MJ, Ruby CE, Redmond WL, et al. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 2008;68(13):5206–5215.
   PubMed Web of Science ®Google Scholar
• Gough MJ, Crittenden MR, Sarff M, et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010;33(8):798–809.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, et al. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1. Expert Opin Ther Pat. 2019;29(7):481–485.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert Opin Ther Pat. 2019;29(5):311–314.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, et al. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. Expert Opin Ther Pat. 2019;29(12):921–924.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. LAG-3 antagonists by cancer treatment: a patent review. Expert Opin Ther Pat. 2019;29(8):643–651.
   PubMed Web of Science ®Google Scholar
• Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205(4):825–839.
   PubMed Web of Science ®Google Scholar
• Valzasina B, Guiducci C, Dislich H, et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105(7):2845–2851.
   PubMed Web of Science ®Google Scholar
• Ruby CE, Yates MA, Hirschhorn-Cymerman D, et al. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol. 2009;183(8):4853–4857.
   PubMed Web of Science ®Google Scholar
• Voo KS, Foglietta M, Percivalle E, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014;135(12):2834–2846.
   PubMed Web of Science ®Google Scholar
• Murata K, Nose M, Ndhlovu LC, et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol. 2002;169(8):4628–4636.
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Review Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4(6):420–431.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Czerwinski DK, Levy R. Timing and sequence of CpG and anti-OX40 is critical for in situ vaccination. Cancer Immunol Res. 2019;7(2):B128.
   Google Scholar
• Sagiv-Barfi I, Czerwinski DK, Levy R. In situ vaccination with a TLR9 agonist and anti-OX40 antibody leads to tumor regression and induces abscopal responses in murine lymphoma. Blood. 2016;128(22):1847.
   Web of Science ®Google Scholar
• Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade. OncoImmunology. 2014;3(3):e28245.
   PubMed Web of Science ®Google Scholar
• Smith N, García-Martínez E, Pitter MR, et al. Trial Watch: toll-like receptor agonists in cancer immunotherapy. OncoImmunology. 2018;7(12):e1526250.
   PubMed Web of Science ®Google Scholar
• Timperi E, Pacella I, Schinzari V, et al. Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer. Oncoimmunology. 2016;5(7):Article: e1175800.
   PubMed Web of Science ®Google Scholar
• Jia Y, Omri A, Krishnan L, et al. Potential applications of nanoparticles in cancer immunotherapy. Hum Vaccin Immunother. 2017;13(1):63–74.
   PubMed Web of Science ®Google Scholar
• Chen W. Novel cancer vaccines. Expert Opin Ther Pat. 2001;11(6):937–950.
   Web of Science ®Google Scholar
• Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs. 2008;13(2):295–308.
   PubMed Web of Science ®Google Scholar
• Kanwar JA, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20(12):1723–1737.
   PubMed Web of Science ®Google Scholar
• Bowen WS, Svrivastava AK, Batra L, et al. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines. 2018;17(3):207–215.
   PubMed Web of Science ®Google Scholar
• Baumgaertner P, Nunes CC, Cachot A, et al. Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology. 2016;5(10):e1216290.
   PubMed Web of Science ®Google Scholar
• Cabral BP, Fonseca MGD, Mota FB. The recent landscape of cancer research worldwide: a bibliometric and network analysis. Oncotarget. 2018;9:30474–30484.
   PubMedGoogle Scholar
• Cabral BP, Derengowski GF, Batista M, et al. What is the future of cancer care? A technology foresight assessment of experts´ expectations. Econ Innovation New Technol. 2018;28(6):635–652.
   Web of Science ®Google Scholar
• European Patent Office. [cited 2019 Mar 25]. Available from: https://www.epo.org/index.html
   Google Scholar
• Patents families. European Patent Office. [cited 2019 Mar 25]. Available from: https://www.epo.org/searching-for-patents/helpful-resources/first-time-here/patent-families.html
   Google Scholar
• Noelle R, Ahonen CL, Kedl RM, inventors; 3M, Dartmouth College. Applicants. Immunostimulatory Combinations. PCT patent WO2004060319. 2003.
   Google Scholar
• Chen JC, Keltner L, Naimushin AN, inventors; Chen, J. C.; Keltner, L.; Naimushin, A. N. Applicants. Tumor vaccination systems, devices, and methods. PCT patent WO201844888. 2017.
   Google Scholar
• Jost C, Buechler J, Valkirs G; et al. inventors; University Of California. Applicant. Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function. PCT patent WO2016205566. 2016.
   Google Scholar
• Willert K, Carson D, inventors; University Of California. Applicant. Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function. PCT patent WO2016205551. 2016.
   Google Scholar
• Salem AK, Makkouk A, Joshi VB; et al. inventors; University Of Iowa Research Foundation. Applicant. Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy. PCT patent WO2016187122. 2016.
   Google Scholar
• Bae J, Munshi NC, Anderson KC, inventors; Dana Farber Cancer Institute. Applicant. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer. PCT patent WO201946818. 2018.
   Google Scholar
• Thanos C, Glickman L, Skoble J, inventors; Actym Therapeutics. Applicant. Engineered immunostimulatory bacterial strains and uses thereof. PCT patent WO201914398. 2018.
   Google Scholar
• Lu B, Yao H, Guo W, inventors; Tsinghua University. Applicant. Novel method for producing antibodies. PCT patent WO2018205917. 2018.
   Google Scholar
• Avigan D, Rosenblatt J, Kufe D, inventor; Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute. Applicants. Compositions and methods of treating câncer. PCT patent WO2017087954. 2016.
   Google Scholar
• Szalay A, Minev B, inventors; Calidi Biotherapeutics, Stemimmune. Applicants. Combination immunotherapy approach for treatment of cancer. PCT patent WO2016065330. 2015.
   Google Scholar
• Li L. inventor; Birdie Biopharmaceuticals, Shanghai Birdie Biotech, Shanghai Bodi Biotechnology, Shanghai Buddy Biotech. Applicants. Compounds for targeted immunotherapy. China patent CN103566377. 2012.
   Google Scholar
• Mukherjee P, Inventor; Mukherjee, P.; University Of North Carolina At Charlotte. Applicants. Tumor specific antibodies and uses therefor. USA patent US20110123442. 2010.
   Google Scholar
• Sun K, Wang J, Wang Z, inventors; Tesaro. Applicant. Combination therapies for treating cancer. PCT patent WO2018213732. 2018.
   Google Scholar
• Goldberg MS, Park CG, inventors; Dana Farber Cancer Institute. Applicant. Drug delivery compositions and uses thereof. PCT patent WO201845058. 2017.
   Google Scholar
• Dranoff G, Sabatos-Peyton CA, Brannetti B; et al. inventors; Dana Farber Cancer Institute, Novartis, The Children's Medical Center. Applicants. Combination therapies comprising antibody molecules to tim-3. PCT patent WO2017019897. 2016.
   Google Scholar
• Dranoff G, Triebel F, Brignone C; et al. inventors; Immutep, Novartis. Applicants. Combination therapies comprising antibody molecules to lag-3. PCT patent WO2017019894. 2016.
   Google Scholar
• Dranoff G, Freeman GJ, Sharpe AH; et al. inventors; Dana Farber Cancer Institute, Harvard College, Novartis, President & Fellows Of Harvard College. Applicants. Combination therapies comprising antibody molecules to pd-1. PCT patent WO2017019896. 2016.
   Google Scholar
• Petit R, Wallecha A, Paterson Y; et al. inventors; Advaxis Inc., The Trustees of The University Of Pennsylvania. Applicants. Combination therapies with recombinant listeria strains. PCT patent WO2016100924. 2015.
   Google Scholar
• Guo L. Inventor; Hangzhou Pooling Biotech. Applicant. Chimeric antigen receptor using GD2 as target and medicine composition. China patent CN109096405. 2018.
   Google Scholar
• Krieg AM inventor; Checkmate Pharmaceuticals. Applicant. Fc receptor-mediated drug delivery. PCT patent WO2017173334. 2017.
   Google Scholar
• Lin HY, Woolf CJ, Menhall T; et al. inventors; Ferrumax Pharmaceuticals, Massachusetts General Hospital, The Children's Medical Center. Applicants. Method of reducing tolerization of T cells to tumor antigens. PCT patent WO2017139405. 2017.
   Google Scholar
• Biel M, Makings LR, Heim R; et al. inventors; Aspyrian Therapeutics, Rakuten Aspyrian. Applicants. Compositions, combinations and related methods for photoimmunotherapy. PCT patent WO2017031367. 2016.
   Google Scholar
• Getts RC, Kadushin JM, Getts L inventors; Genisphere. Applicant. Nucleic acid carriers and therapeutic methods of use. PCT patent WO2017143171. 2017.
   Google Scholar
• Chang TW, Chu H-M, Chen J-H; et al. inventors; Academia Sinica, Immunwork. Applicants. Molecular constructs with targeting and effector elements. PCT patent WO2016112870. 2016.
   Google Scholar
• Moon JJ, Kuai R, Schwendeman AA; et al. inventors; University of Michigan. Applicant. Compositions and methods for delivery of biomacromolecule agents. US Patent US20180078625. 2016.
   Google Scholar
• Moon JJ, Schwendeman AA, Kuai R; et al. inventors; University Of Michigan. Applicant. Compositions and methods for delivery of biomacromolecule agentes. PCT patent WO2017223085. 2017.
   Google Scholar
• Nam J, Moon JJ, Kuai R; et al. inventors; University Of Michigan. Applicant. Compositions and methods for delivery of biomacromolecule agents. PCT patent WO2016154544. 2016.
   Google Scholar
• Moon JJ, Fan Y, NAM J. inventors; University of Michigan. Applicant. Compositions and methods for delivery of polymer/biomacromolecule conjugates. PCT patent WO2018156617. 2018.
   Google Scholar
• Van Roosmalen MH, Semjonow V, Nieuwenhuis JH; et al. inventors; PHILIPS. Applicant. Diagnostic method employing hnl. PCT patent WO2016079219. 2015.
   Google Scholar
• Stewart RA, Tigue NJ, Young LL; et al. inventors; Medimmune. Applicant. Gitrl fusion proteins and uses thereof. PCT patent WO2017/025610. 2016.
   Google Scholar
• Petit R, Wallecha A, Khleif S; et al. inventors; Us Dep. Health and Human Services (Nhs), Advaxis Inc. Applicants. Listeria-based immunogenic compositions for eliciting anti-tumor responses. PCT patent WO2016011362. 2015.
   Google Scholar
• Brix L, Schoeller J, Pedersen H. inventors; Dako Denmark. Applicant. Mhc multimers in cancer vaccines and immune monitoring. PCT patent WO2010037395. 2009.
   Google Scholar
• Schoeller J, Pedersen H, Brix L inventors; Dako Denmark. Applicant. Molecular vaccines for infectious disease. PCT patent WO2010037402. 2009.
   Google Scholar
• Block D, Olsen H inventors Olsen Henrik, Gliknik. Applicants. Molecules with antigen binding and polyvalent fc gamma receptor binding activity. PCT patent WO2014031646. 2013.
   Google Scholar
• Seymour LCW, Fisher K Psioxus Therapeutics Ltd. Applicants. Multi-valent adjuvant display. Great Britain patent GB0907989. 2009.
   Google Scholar
• Flechtner JB, Lossky EM, Carroll PM; et al. inventors; Genocea Biosciences. Applicant. Treatment methods. PCT patent WO2018175505. 2018.
   Google Scholar
• Dako Denmark A/S. Bloomberg. [cited 2019 Apr 23]. Available from: https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=278157113
   Google Scholar
• Dako Products. Agilent. [cited 2019 Apr 23]. Available from: https://www.agilent.com/en/dako-products
   Google Scholar
• Advaxis Immunotherapies. [cited 2019 Apr 23]. Available from: https://www.advaxis.com
   Google Scholar
• Berkeley University of California. [cited 2019 Apr 23]. Available from: https://www.berkeley.edu/about
   Google Scholar
• Novartis; 2019 [cited 2019 Apr 23]. Available from: https://www.novartis.com/
   Google Scholar
• University of Michigan. [cited 2019 Apr 23]. Available from: https://umich.edu/about/
   Google Scholar
• Dana-Faber Cancer Institute. [cited 2019 Apr 23]. Available from: https://www.dana-farber.org
   Google Scholar
• The Children’s Medical Center Hospital. Bloomberg. [cited 2019 Apr 23]. Available from: https://www.bloomberg.com/profile/company/0352162D:US.
   Google Scholar
• SD-110, 2020 - TLR9 agonist SD-101, Drug Dictionary, United States National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr9-agonist-sd-101. Access 2020 Jan 27.
   Google Scholar
• Levy R TLR9 agonist SD-101, Anti-OX40 antibody BMS 986178, and radiation therapy in treating patients with low-grade B-Cell non-Hodgkin lymphomas. Clinical Trials Identifier NCT03410901. United States National Library of Medicine. [cited 2019 Apr 23]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03410901?term=OX-40+and+CPG&rank=2
   Google Scholar
• Kummar S, Bristol-Myers S SD-101 and BMS-986178 in treating patients with advanced or metastatic solid malignancies. Clinical Trials Identifier NCT03831295. United States National Library of Medicine. [cited 2019 Apr 23]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03831295?term=OX-40+and+CPG&rank=1
   Google Scholar